Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced…

Continue ReadingAllogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Read more about the article ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

ALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

Continue ReadingALPHA3: A Pivotal Phase 2 Study of First‑Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients (Pts)  With Large B‑Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy